For PPP2R1B elevation, a recent study has demonstrated that the upregulation of the PPP2R1B gene, directly targeted by the transcription factor IRF3, is associated with increased dysglycemia and impaired glucose regulation in patients with obesity and non-alcoholic fatty liver disease [72]. This evidence concerns the gene IRF3 and metabolic dysfunction-associated steatotic liver disease.